Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

First clinical results on mGluR5 tracer [18F]PSS-232

June 17, 2015

No Comments

Atara Biotherapeutics exercises option to T-cell technology from MSK

June 16, 2015

No Comments

First clinical results for nAChR tracer [18F]XTRA

June 16, 2015

No Comments

Compugen selects new B7/CD28-like target for further development

June 10, 2015

No Comments

Symbiotix Biotherapies awarded NIAID grant to develop microbiome-derived therapeutics

June 8, 2015

No Comments

ProLynx cleared to start phase I trial of PEG-SN-38

June 4, 2015

No Comments

Biotest and Affibody sign Albumod research license and option agreement

June 4, 2015

No Comments

Arch enters R&D collaboration with CURAM

June 3, 2015

No Comments

Medifocus obtains option to license cancer immunotherapy technology from Duke University

June 2, 2015

No Comments

Padlock Therapeutics licenses protein-arginine deiminase assets from GSK

June 2, 2015

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Drug design, drug delivery and technologies
RSS

First clinical results on mGluR5 tracer [18F]PSS-232

Atara Biotherapeutics exercises option to T-cell technology from MSK

First clinical results for nAChR tracer [18F]XTRA

Compugen selects new B7/CD28-like target for further development

Symbiotix Biotherapies awarded NIAID grant to develop microbiome-derived therapeutics

ProLynx cleared to start phase I trial of PEG-SN-38

Biotest and Affibody sign Albumod research license and option agreement

Arch enters R&D collaboration with CURAM

Medifocus obtains option to license cancer immunotherapy technology from Duke University

Padlock Therapeutics licenses protein-arginine deiminase assets from GSK

Today's news in brief

Today's news in brief

Second insulin receptor offers new therapeutic avenues

Mechanism underlying so-called idiopathic autism inception unveiled

Keros stock wilts as it halts two dosing arms in hypertension study

Drug design, drug delivery and technologies RSS

Drug design, drug delivery and technologies
RSS